Abstract
Crizotinib as an ALK/ROS1/MET inhibitor, is highly effective against ROS1-rearranged lung cancer. However, similar to other oncogene-driven lung cancers, ROS1-rearranged lung cancers treated with crizotinib eventually acquired resistance. In our study, we examined the profiles of ROS1 resistance mutations and co-occurring genetic alterations after crizotinib treatment.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Annals of oncology : official journal of the European Society for Medical Oncology
Paper Title
Journal
Date
